Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBACLOFEN (baclofen) by Rubicon Biotechnology is gaba a agonists [moa]. Approved for spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms, concomitant pain and 5 more indications. First approved in 2024.
Drug data last refreshed 20h ago
GABA A Agonists
gamma-Aminobutyric Acid-ergic Agonist
Worked on BACLOFEN at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Intrathecal Baclofen and Pediatric Dystonia
A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers
Intrathecal (IT) Baclofen Drug Distribution
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP). Preliminary Study.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo